IPF

This study tested a drug called MN-001 in 15 people with moderate to severe idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. Participants took either MN-001 or a placebo twice daily for 6 months, followed by an open-label phase wher…

This study tested an oral drug called GRI-0621 in 35 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. The main goal was to check safety and how the drug affects certain biomarkers in the blood. Participants took either t…

This early-stage study tested a new drug called PMG1015 in 29 people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. The main goal was to check if the drug is safe and how the body processes it. Participants received either th…

This study involved 30 people newly diagnosed with idiopathic pulmonary fibrosis (IPF). Researchers tested a short questionnaire to see if it could accurately identify each patient's need for palliative care, such as symptom management or home support. The goal was to make it eas…

This study looked at 143 adults with different types of lung scarring (IPF and hypersensitivity pneumonitis) to see how well three scoring systems—GAP, ILD-GAP, and CPI—predict survival. Researchers compared medical records to find out which score works best for each disease type…

This early-stage study tested a new drug called HLX6018 in 66 healthy adults to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. Participants received a single dose of the drug or…